Senolytic agents selectively eliminate senescent cells — irreversibly growth-arrested cells that accumulate with aging and secrete a toxic cocktail of pro-inflammatory cytokines, chemokines, and proteases known as the senescence-associated secretory phenotype (SASP). In the aging brain, senescent astrocytes, microglia, oligodendrocyte precursors, and endothelial cells drive chronic neuroinflammation that accelerates tau pathology, synaptic loss, and neuronal death. The landmark 2018 study by Bussian and colleagues in Nature demonstrated that genetic clearance of senescent glial cells in tau P301S mice prevented neurofibrillary tangle formation, neurodegeneration, and cognitive decline — establishing a direct causal link between cellular senescence and tau-dependent neurodegeneration. This finding is directly relevant to corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), both defined by accumulation of hyperphosphorylated 4R-tau, and has catalyzed clinical trials of the dasatinib + quercetin (D+Q) combination and fisetin in neurodegenerative diseases.
Cellular senescence is triggered by diverse stressors — telomere shortening, DNA damage, oxidative stress, oncogene activation, and mitochondrial dysfunction — and maintained by the p53/p21CIP1 and p16INK4a/Rb tumor suppressor pathways[1]. Unlike apoptotic cells (which are rapidly cleared), senescent cells persist indefinitely and resist programmed cell death by upregulating anti-apoptotic Bcl-2 family proteins (Bcl-2, Bcl-xL, Bcl-w)[2]. This survival dependency creates a therapeutic vulnerability: drugs that inhibit Bcl-2 family proteins selectively kill senescent cells while sparing normal cells with redundant survival mechanisms.
The SASP amplifies neurodegeneration through multiple mechanisms:
In neurodegenerative tauopathies, the SASP creates a feed-forward loop: tau pathology induces glial senescence, senescent glia produce SASP, SASP promotes tau phosphorylation and aggregation, which induces further senescence[4][5].
Astrocytes: SA-β-gal-positive senescent astrocytes accumulate around neurofibrillary tangles. Senescent astrocytes lose neuroprotective functions (glutamate clearance, BDNF secretion, metabolic support) while gaining neurotoxic SASP secretion[6].
Microglia: Dystrophic, senescent microglia with p16INK4a expression show impaired phagocytic capacity — they can no longer efficiently clear tau aggregates or cellular debris, further accelerating pathology[7].
Oligodendrocyte precursors (OPCs): Senescent OPCs fail to differentiate and remyelinate, contributing to the white matter degeneration prominent in PSP[8].
Endothelial cells: Blood-brain barrier endothelial senescence increases permeability, allowing peripheral immune infiltration and disrupting neurovascular coupling[9].
Dasatinib is a multi-kinase inhibitor (FDA-approved for chronic myeloid leukemia) that blocks Src family kinases and BCR-ABL, disabling anti-apoptotic signaling in senescent cells[10]. Quercetin is a flavonoid that inhibits PI3K, Akt, Bcl-2, and Mcl-1, complementing dasatinib's mechanism[11]. The combination was identified through a systematic screen by Zhu and colleagues at the Mayo Clinic, who demonstrated that neither drug alone was sufficient for broad senolytic activity — the combination exploits the multi-pathway survival dependency of senescent cells[10:1].
Key pharmacological features:
Fisetin (3,7,3',4'-tetrahydroxyflavone) is a naturally occurring flavonoid found in strawberries, apples, and persimmons with potent senolytic activity discovered by Yousefzadeh and colleagues[12]. Fisetin targets PI3K/Akt/mTOR and Bcl-2/Bcl-xL pathways and shows approximately 2-fold greater senolytic potency than quercetin in some assays. Advantages over D+Q include:
Fisetin reduced senescent cell burden and extended median and maximum lifespan in naturally aged mice when administered intermittently (500 mg/kg for 5 consecutive days, monthly)[12:1].
Navitoclax: A direct Bcl-2/Bcl-xL inhibitor with potent senolytic activity but dose-limiting thrombocytopenia that limits clinical use[13]. More selective agents targeting Bcl-xL alone (e.g., A1331852) are in development.
UBX0101: A p53/MDM2 interaction inhibitor tested in osteoarthritis but discontinued after Phase II failure. Lessons from this program inform neurodegenerative applications[14].
The most compelling preclinical evidence comes from Bussian and colleagues' 2018 Nature paper using the PS19 (tau P301S) mouse model[4:1]:
This study is directly relevant to CBS/PSP because the PS19 model expresses human 4R-tau P301S — the same tau isoform and class of mutations driving CBS/PSP pathology.
Musi and colleagues demonstrated that tau protein aggregation directly induces cellular senescence in human brain tissue, with senescent cell markers co-localizing with tau pathology across the Braak staging spectrum[5:1]. In rTg4510 mice (expressing P301L tau), senescent cells appeared before overt neurodegeneration, and their density predicted subsequent neuronal loss — establishing senescence as an early, potentially reversible event in the tau pathology cascade.
In APP/PS1 mice, D+Q treatment reduced amyloid plaque burden, decreased SASP markers, and improved hippocampal neurogenesis and cognitive function on novel object recognition and contextual fear conditioning[15]. The Alzheimer's Drug Discovery Foundation-funded SToMP-AD trial (Senolytic Therapy to Modulate Progression of Alzheimer's Disease) translated these findings to human patients[16].
The SToMP-AD trial (NCT04063124) was a pioneering open-label Phase I study of D+Q in early-stage Alzheimer's disease[16:1]:
The ALSENLITE trial (NCT04785300) tested D+Q in ALS, another neurodegenerative condition with evidence of cellular senescence[17]. The trial demonstrated safety and suggested potential slowing of functional decline, though the study was not powered for efficacy.
AFFIRM-LITE (NCT03675724): Phase II trial of fisetin (100 mg/kg, 2 consecutive days, monthly) in frail elderly adults showed reduction in SASP markers (IL-6, MMP-3) at 3 months with favorable safety[18].
Fisetin is also being studied in COVID-related senescence (NCT04476953) and osteoarthritis, generating safety data applicable to neurodegenerative indications.
CBS and PSP represent particularly compelling indications for senolytic therapy because:
Based on the Bussian et al. data and CBS/PSP pathobiology:
| Parameter | Recommendation |
|---|---|
| Dasatinib dose | 100 mg oral |
| Quercetin dose | 1000 mg oral (liposomal preferred) |
| Schedule | 2 consecutive days, then 14 days off (Kirkland protocol) |
| Cycle length | 2 days on / 12–14 days off |
| Duration | 6 cycles minimum (12 weeks) for initial assessment |
| Timing | Morning, with food (improves quercetin absorption) |
| Parameter | Recommendation |
|---|---|
| Dose | 20 mg/kg/day (approximately 1000–1500 mg for 70 kg adult) |
| Formulation | Liposomal fisetin (standard fisetin has <10% bioavailability) |
| Schedule | 2 consecutive days monthly (per AFFIRM-LITE) |
| Duration | 6 months minimum for assessment |
D+Q at intermittent senolytic doses has shown favorable safety across multiple trials[22]:
Fisetin safety: No dose-limiting toxicity at up to 20 mg/kg in clinical trials. GI upset is the most common side effect[18:1].
Before starting: CBC with differential, comprehensive metabolic panel, ECG (baseline QTc), coagulation studies
During treatment: CBC on day 7 of first cycle; repeat if thrombocytopenia; symptom diary for fatigue, bruising, bleeding
Every 3 cycles: CBC, liver function, renal function; clinical assessment (PSP Rating Scale or CBS functional measures)
Senolytics address the senescence pathway specifically and combine rationally with interventions targeting other aspects of tauopathy:
| Combination | Rationale |
|---|---|
| D+Q + Rapamycin | Senolysis + autophagy enhancement |
| D+Q + Spermidine | Senolysis + EP300-mediated autophagy |
| D+Q + Lithium | Senolysis + GSK-3β inhibition |
| D+Q + NAD+ precursors | Senolysis + mitochondrial support |
| Fisetin + Melatonin | Senolysis + antioxidant + chronobiology |
| Dimension | Score | Rationale |
|---|---|---|
| Mechanistic Clarity | 9/10 | Bcl-2 dependency well-characterized; Bussian 2018 definitive |
| Clinical Evidence | 4/10 | SToMP-AD Phase I only; no efficacy data in tauopathy |
| Preclinical Evidence | 8/10 | P301S tau mouse data directly relevant; multiple models |
| Replication | 6/10 | Bussian replicated; D+Q effects confirmed in multiple groups |
| Effect Size | 6/10 | Strong prevention in mice; therapeutic effects more modest |
| Safety/Tolerability | 7/10 | Intermittent dosing well-tolerated; dasatinib requires monitoring |
| Biological Plausibility | 9/10 | Direct causal evidence linking senescence to tau pathology |
| Actionability | 5/10 | D+Q requires prescription (dasatinib); fisetin OTC but unproven |
| Total | 54/80 |
Priority trial design: A Phase Ib/II study of D+Q in PSP-Richardson syndrome with tau PET (18F-MK-6240), CSF p-tau-217, and NfL as biomarker endpoints, combined with PSPRS clinical outcomes.
Ideal CBS/PSP candidates for senolytic therapy:
Senolytic dosing days (2 days/month) may cause transient fatigue. Schedule physical therapy, cognitive stimulation, and rehabilitation activities on non-dosing weeks to avoid interference with exercise participation.
He S, Sharpless NE. Senescence in health and disease. Cell. 2017. ↩︎
Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015. ↩︎
Acosta JC, Banito A, Wuestefeld T, et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nature Cell Biology. 2013. ↩︎
Bussian TJ, Aziz A, Meyer CF, et al. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature. 2018. ↩︎ ↩︎
Musi N, Valentine JM, Sickora KR, et al. Tau protein aggregation is associated with cellular senescence in the brain. Aging Cell. 2018. ↩︎ ↩︎
Bhat R, Crowe EP, Bitto A, et al. Astrocyte senescence as a component of Alzheimer's disease. PLoS ONE. 2012. ↩︎
Streit WJ, Braak H, Xue QS, Bechmann I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathologica. 2009. ↩︎ ↩︎
Zhang P, Kishimoto Y, Grammatikakis I, et al. Senolytic therapy alleviates Aβ-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer's disease model. Nature Neuroscience. 2019. ↩︎
Yamazaki Y, Baker DJ, Bhatt N, Bhattacharyya A. Vascular cell senescence contributes to blood-brain barrier breakdown. Stroke. 2016. ↩︎
Zhu Y, Tchkonia T, Pirtskhalava T, et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell. 2017. ↩︎ ↩︎
Siegelin MD, Reuss DE, Habel A, et al. Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells. Neuro-Oncology. 2009. ↩︎
Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018. ↩︎ ↩︎
Chang J, Wang Y, Shao L, et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nature Medicine. 2016. ↩︎
Jeon OH, Kim C, Laberge RM, et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nature Medicine. 2017. ↩︎
Ogrodnik M, Evans SA, Fielder E, et al. Whole-body senescent cell clearance alleviates age-related brain inflammation and cognitive impairment in mice. Aging Cell. 2021. ↩︎
Gonzales MM, Garbarino VR, Marber MS, et al. Senolytic therapy to modulate the progression of Alzheimer's disease (SToMP-AD): a pilot clinical trial. Journal of Prevention of Alzheimer's Disease. 2023. ↩︎ ↩︎
Geng YQ, Guan JT, Xu MY, et al. Senescence-associated beta-galactosidase activity expression in aging hippocampal neurons. Biochemical and Biophysical Research Communications. 2010. ↩︎
Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 2019. ↩︎ ↩︎
Kovacs GG, Ferrer I, Grinberg LT, et al. Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathologica. 2016. ↩︎
Dickson DW, Ahmed Z, Algom AA, et al. Neuropathology of variants of progressive supranuclear palsy. Current Opinion in Neurology. 2010. ↩︎
Höglinger GU, Melhem NM, Dickson DW, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nature Genetics. 2011. ↩︎
Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 2019. ↩︎
Gasek NS, Kuchel GA, Kirkland JL, Xu M. Strategies for targeting senescent cells in human disease. Nature Aging. 2021. ↩︎
Kirkland JL, Tchkonia T. Clinical strategies and animal models for developing senolytic agents. Experimental Gerontology. 2015. ↩︎